Hutchmed, Innovent Combo Therapy Hits PFS Target in Renal Cancer Study

MT Newswires Live03-19

HUTCHMED (China) (HKG:0013) and Innovent Biologics (HKG:1801) said their FRUSICA-2 Phase II/III study of fruquintinib in combination with sintilimab as a second line of treatment for advanced renal cell carcinoma in China met its primary endpoint of progression-free survival (PFS).

Іn addition to the primary endpoint, the combination therapy also demonstrated improvements in secondary endpoints including objective response rate and duration of response.

Complete results will be presented at an upcoming conference, according to a Wednesday filing with the Hong Kong bourse.

The combo therapy also secured conditional approval for treating advanced endometrial cancer from China's National Medical Products Association.

Hutchmed's shares were up by 4%, while those of Innovent were down 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2520941088?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-19 15:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520941088","market":"nz","top_or_hot":-1,"title":"Hutchmed, Innovent Combo Therapy Hits PFS Target in Renal Cancer Study","media":"MT Newswires Live","content":"<html><body><p> HUTCHMED (China) (HKG:0013) and Innovent Biologics (HKG:1801) said their FRUSICA-2 Phase II/III study of fruquintinib in combination with sintilimab as a second line of treatment for advanced renal cell carcinoma in China met its primary endpoint of progression-free survival (PFS).</p><p>Іn addition to the primary endpoint, the combination therapy also demonstrated improvements in secondary endpoints including objective response rate and duration of response.</p><p>Complete results will be presented at an upcoming conference, according to a Wednesday filing with the Hong Kong bourse.</p><p>The combo therapy also secured conditional approval for treating advanced endometrial cancer from China's National Medical Products Association.</p><p>Hutchmed's shares were up by 4%, while those of Innovent were down 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hutchmed, Innovent Combo Therapy Hits PFS Target in Renal Cancer Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHutchmed, Innovent Combo Therapy Hits PFS Target in Renal Cancer Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-19 15:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> HUTCHMED (China) (HKG:0013) and Innovent Biologics (HKG:1801) said their FRUSICA-2 Phase II/III study of fruquintinib in combination with sintilimab as a second line of treatment for advanced renal cell carcinoma in China met its primary endpoint of progression-free survival (PFS).</p><p>Іn addition to the primary endpoint, the combination therapy also demonstrated improvements in secondary endpoints including objective response rate and duration of response.</p><p>Complete results will be presented at an upcoming conference, according to a Wednesday filing with the Hong Kong bourse.</p><p>The combo therapy also secured conditional approval for treating advanced endometrial cancer from China's National Medical Products Association.</p><p>Hutchmed's shares were up by 4%, while those of Innovent were down 1% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2520941088","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520941088","pubTimestamp":1742368479,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HUTCHMED (China) (HKG:0013) and Innovent Biologics (HKG:1801) said their FRUSICA-2 Phase II/III study of fruquintinib in combination with sintilimab as a second line of treatment for advanced renal ce","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1191":"制药","BK1589":"北水核心资产","PFS":"Provident Financial Services Inc","BK1583":"高瓴概念","BK1587":"次新股","01801":"信达生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4211":"区域性银行","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1588":"回港中概股","00013":"和黄医药","BK4195":"互助储蓄与抵押信贷金融服务"},"translate_title":"和黄医药、信达生物联合疗法在肾癌研究中达到PFS目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"01801":0.9,"PFS":1},"content_text":"HUTCHMED (China) (HKG:0013) and Innovent Biologics (HKG:1801) said their FRUSICA-2 Phase II/III study of fruquintinib in combination with sintilimab as a second line of treatment for advanced renal cell carcinoma in China met its primary endpoint of progression-free survival (PFS).Іn addition to the primary endpoint, the combination therapy also demonstrated improvements in secondary endpoints including objective response rate and duration of response.Complete results will be presented at an upcoming conference, according to a Wednesday filing with the Hong Kong bourse.The combo therapy also secured conditional approval for treating advanced endometrial cancer from China's National Medical Products Association.Hutchmed's shares were up by 4%, while those of Innovent were down 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2520941088"}